Full Professor(heuristic)

Lung Cancer Treatments and Mutations · Pulmonary and Respiratory Medicine

Compare more Pulmonary and Respiratory Medicine professors.

h-index110
i10-index489
Publications1,170
Citations49,298

Grants

10 total · 1 active

NIH #R01CA262292

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$600K–$700K
Period
2022-06-01 → 2027-05-31
PIs
2

Awarded at UNIVERSITY OF WISCONSIN-MADISON

NIH #R01CA247471

Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer

Amount
$600K–$700K
Period
2019-12-20 → 2024-11-30
PIs
3

Awarded at UNIVERSITY OF NEBRASKA MEDICAL CENTER

NIH #R01CA129501

Role of Paxillin in Lung Cancer

Amount
$300K–$400K
Period
2008-06-02 → 2013-04-30
PIs
1

Awarded at UNIVERSITY OF CHICAGO

Active grants are a starting point, not proof of an opening. Confirm recruiting and funding with the professor, current students, and your written offer. Learn how to verify PhD funding →

All Grants

10 total · 1 active

NIH #R01CA262292

Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC

Active
Amount
$600K–$700K
Period
2022-06-01 → 2027-05-31
PIs
2

Awarded at UNIVERSITY OF WISCONSIN-MADISON

NIH #R01CA247471

Modulation of Tumor Microenvironment for Improved Therapy of Pancreatic Cancer

Amount
$600K–$700K
Period
2019-12-20 → 2024-11-30
PIs
3

Awarded at UNIVERSITY OF NEBRASKA MEDICAL CENTER

NIH #R01CA129501

Role of Paxillin in Lung Cancer

Amount
$300K–$400K
Period
2008-06-02 → 2013-04-30
PIs
1

Awarded at UNIVERSITY OF CHICAGO

NIH #R01CA100750

Role of c-Met in SCLC and Potential for Novel Therapy

Amount
$200K–$300K
Period
2004-03-01 → 2013-02-28
PIs
1

Awarded at UNIVERSITY OF CHICAGO

NIH #R21CA140003

Novel Targeted Therapy in Pancreatic Cancer

Amount
$200K–$300K
Period
2009-03-01 → 2012-02-28
PIs
2

Awarded at UNIVERSITY OF CHICAGO

NIH #R01CA125541

Studies of a Novel Therapeutic Target in Non-Small Cell Lung Cancer (NSCLC)

Amount
$200K–$300K
Period
2007-01-15 → 2011-11-30
PIs
1

Awarded at UNIVERSITY OF CHICAGO

NIH #R21CA081324

MINIMAL RESIDUAL TUMOR IN SMALL CELL LUNG CANCER

Amount
<$100K
Period
1999-04-05 → 2003-03-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #R29CA075348

ABNORMALITIES OF MOTILITY OF CML CELLS

Amount
$100K–$200K
Period
1997-08-01 → 2002-07-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #K08CA060821

PAXILLIN--AN ONCOGENE ACTIVATED PROTEIN

Amount
<$100K
Period
1993-08-15 → 1996-07-31
PIs
1

Awarded at DANA-FARBER CANCER INST

NIH #P01HL058064

Hepatocyte Growth Factor/c-Met Invovement in Lung EC Barrier Regulation

Amount
$300K–$400K
Period
— → —
PIs
1

Awarded at UNIVERSITY OF ILLINOIS AT CHICAGO

Recent Public Signals

  1. New paper: Personal pathways to success: an innovative program to overcome cancer patient barriers to tobacco cessation and promote patient participation (Supportive Care in Cancer)2026-07-01
  2. New preprint: Cancer Survival at a Comprehensive Cancer Center Compared with Surveillance, Epidemiology, and End Results (SEER) Estimates2025-09-08
  3. New NIH award: Cooperation of the TAM and Abl family kinases in therapeutic resistance in HNC2022-06-01

Are you this professor?

No account needed — verify once with your ORCID iD to set recruiting status and correct your rank.

Data Freshness

  • Publications as of 2026-07-09
  • Grants as of 2026-09-03

Data may not be current

Find elsewhere

Institution / lab homepage Search on ResearchGate

ORCID: 0000-0001-9643-7626

Professor Insights

Career Trajectory